Sarepta Therapeutics’ $1.15 Billion Notes Offering

Goodwin Procter advised the initial purchasers on the deal.Sarepta Therapeutics, Inc. announced its Rule 144A offering of 1.25% Convertible Senior Notes due 2027. The $1.15 billion offering…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now